Decitabine/ Tetrahydrouridine (NDec)
Small molecule
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ASCENT1 NCT05405114 · Sickle Cell Disease Registry: NCT05405114 | 2 | Change in total haemoglobin (From baseline (week 0) to week 24) 2025-07-24 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT01685515 NCT01685515 · Sickle Cell Disease Registry: NCT01685515 | 1 | Non-hematologic toxicity (12 weeks) 2018-06 | Primary safety endpoint (grade 3 or higher non-hematologic toxicity) was not triggered; AEs did not differ from placebo. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Competitive landscape
Other DNMT1 (DNA methyltransferase 1) drugs
Azacitidine, Azacitidine (Onureg). Compare all 3 DNMT1 (DNA methyltransferase 1) drugs
2 other tracked programmes target this mechanism, 2 of them ahead of this one.
This drug's own stage for Sickle Cell Disease: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Decitabine / Tetrahydrouridine (NDec): this drug | Phase 2 | Small molecule | DNMT1 (DNA methyltransferase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| Azacitidine | Approved(overall) | Small molecule | DNMT1 (DNA methyltransferase 1) | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Azacitidine (Onureg) | Approved(overall) | Small molecule | DNMT1 (DNA methyltransferase 1) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Crizanlizumab-Tmca (Adakveo) | Approved | Monoclonal antibody | P-selectin | Partial signal | Featured results are non-efficacy only in this race | |
| Exagamglogene Autotemcel (Casgevy) | Approved | Gene therapy / editing | BCL11A erythroid enhancer (gene editing) | Weak signal | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Droxia) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Siklos) | Approved | Small molecule | Ribonucleotide reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Hydroxyurea (Xromi) | Approved | Small molecule | Ribonucleotide reductase | Weak signal | No reviewed efficacy summary in this indication | |
| L-Glutamine (Endari) | Approved | Small molecule | Amino Acid | Reliable signal | NCT01179217: The Number of Occurrences of Sickle Cell Crises (48 weeks): L-glutamine 3 Number of crises (range 0 to 15) | 100% Maltodextrin 4 Number of crises (range 0 to 15) | |
| Lovotibeglogene Autotemcel (Lyfgenia) | Approved | Gene therapy / editing | Beta-globin gene addition (betaA-T87Q) | not yet graded | No reviewed efficacy summary in this indication | |
| Etavopivat | Phase 3 | — | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| Mitapivat (Pyrukynd) | Phase 3 | Small molecule | Pyruvate kinase | not yet graded | No reviewed efficacy summary in this indication | |
| HBI-002 | Phase 2 | Small molecule | Carbon monoxide (CO)-based gas therapeutic; oral liquid CO formulation | not yet graded | No reviewed efficacy summary in this indication | |
| ITU512 | Phase 1/2 | Small molecule | WIZ transcription factor | not yet graded | No reviewed efficacy summary in this indication | |
| Nula-Cel | Phase 1/2 | Gene or cell therapy (subtype unspecified) | HBB gene (sickle mutation correction) | not yet graded | No reviewed efficacy summary in this indication | |
| Ristoglogene Autogetemcel | Phase 1/2 | Gene therapy / editing | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| DISC-3405 | Phase 1 | Monoclonal antibody | TMPRSS6 (matriptase-2) | not yet graded | No reviewed efficacy summary in this indication | |
| SCD-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| VAS-101 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| Iloprost (Ventavis) | Discontinued | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Renizgamglogene Autogedtemcel | Discontinued | Gene or cell therapy (subtype unspecified) | HBG1/HBG2 promoters | not yet graded | No reviewed efficacy summary in this indication | |
| Voxelotor (Oxbryta) | Discontinued | Small molecule | Hemoglobin S (HbS) | Reliable signal | NCT03036813: Haemoglobin response (>1 g/dL rise at week 24): voxelotor 1500 mg 46/90, 900 mg 30/92, placebo 6/92 |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent